Patents Assigned to CSL Limited
-
Patent number: 11957731Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: September 2, 2022Date of Patent: April 16, 2024Assignee: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 11840573Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.Type: GrantFiled: November 20, 2020Date of Patent: December 12, 2023Assignee: CSL LIMITEDInventors: Catherine Owczarek, Con Panousis, Nicholas Wilson, Matthew Hardy, Kirsten Edwards, Veronika Rayzman
-
Publication number: 20230279129Abstract: The present disclosure relates to a method for preventing or treating ischemia-reperfusion injury in a subject the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation. In some examples, the compound is an antibody.Type: ApplicationFiled: January 10, 2023Publication date: September 7, 2023Applicant: CSL LimitedInventors: Ingela VIKSTROM, Adriana BAZ MORELLI, Martin PEARSE
-
Patent number: 11732028Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: GrantFiled: July 31, 2020Date of Patent: August 22, 2023Assignee: CSL LimitedInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Patent number: 11723953Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: July 6, 2021Date of Patent: August 15, 2023Assignee: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20230142696Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: ApplicationFiled: September 2, 2022Publication date: May 11, 2023Applicant: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20230086472Abstract: A serum albumin variant, or functional fragment thereof, comprising, one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).Type: ApplicationFiled: August 30, 2022Publication date: March 23, 2023Applicant: CSL LimitedInventors: Sabine RAUTH, Andrew HAMMET, Kirsten Edwards, Con PANOUSIS
-
Patent number: 11510968Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.Type: GrantFiled: December 2, 2020Date of Patent: November 29, 2022Assignee: CSL LIMITEDInventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
-
Patent number: 11505619Abstract: The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.Type: GrantFiled: December 14, 2018Date of Patent: November 22, 2022Assignee: CSL LimitedInventors: Malgorzata Wygrecka, Marc Nolte, Con Panousis
-
Patent number: 11466073Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).Type: GrantFiled: October 18, 2018Date of Patent: October 11, 2022Assignee: CSL LimitedInventors: Sabine Rauth, Andrew Hammet, Kirsten Edwards, Con Panousis
-
Patent number: 11464828Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: March 23, 2020Date of Patent: October 11, 2022Assignee: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20220133852Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: July 6, 2021Publication date: May 5, 2022Applicant: CSL LimitedInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Patent number: 11279750Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: GrantFiled: September 18, 2019Date of Patent: March 22, 2022Assignee: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 11261243Abstract: The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.Type: GrantFiled: July 24, 2019Date of Patent: March 1, 2022Assignees: CSL LIMITED, B-CREATIVE SWEDEN ABInventors: Ulf Eriksson, Annelie Falkevall, Annika Mehlem
-
Patent number: 11174321Abstract: The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.Type: GrantFiled: April 6, 2017Date of Patent: November 16, 2021Assignee: CSL LIMITEDInventors: Con Panousis, Karlheinz Peter, Hamid Hosseini, Yung-Chih Chen
-
Publication number: 20210292424Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.Type: ApplicationFiled: March 18, 2021Publication date: September 23, 2021Applicant: CSL LIMITEDInventors: Devendra Keshaorao HIWASE, Timothy Peter HUGHES, Angel Francisco LOPEZ, Gino Luigi VAIRO
-
Publication number: 20210269517Abstract: The present disclosure provides a method of treating a wasting disorder in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling. The present disclosure also provides a method of treating cancer cachexia in a subject suffering from cancer cachexia, the method comprising 5 administering to the subject a compound that inhibits VEGF-B signaling.Type: ApplicationFiled: September 18, 2019Publication date: September 2, 2021Applicants: CSL Limited, CSL Innovation Pty Ltd, B-Creative Sweden ABInventors: Ulf ERIKSSON, Annelie FALKEVALL, Annika MEHLEM, Isolde PALOMBO, Samuel WRIGHT
-
Patent number: 11058747Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: GrantFiled: June 19, 2019Date of Patent: July 13, 2021Assignee: CSL LIMITEDInventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20210179721Abstract: The present disclosure relates to a method for preventing or treating ischemia-reperfusion injury in a subject the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation. In some examples, the compound is an antibody.Type: ApplicationFiled: November 29, 2018Publication date: June 17, 2021Applicant: CSL LimitedInventors: Ingela VIKSTROM, Adriana BAZ MORELLI, Martin PEARSE
-
Publication number: 20210147509Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: ApplicationFiled: July 31, 2020Publication date: May 20, 2021Applicant: CSL LimitedInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki